Bright Minds Biosciences Inc. (DRUG)
NASDAQ
$51.80−$1.71 (−3.20%) on the dayAs of the close; data may be delayed.
DRUG price, last 12 months
Key stats
- Previous close
- $53.51
- Open
- $53.33
- Day range
- $51.41 – $54.37
- 52-week range
- $48.90 – $123.75
- Volume
- 211K
- Avg volume (20 days)
- 91.9K
- Market cap
- $508.3M
Performance
1W−15.1%
1M−32.4%
3M−21.3%
6M−29.3%
YTD−33.6%
1Y+1.6%
vs S&P 500, 1Y−15.2 pts
Technicals and fundamentals
About Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
- Listed on
- NASDAQ
- Market cap
- $508.3M